Table 4.
The drugs used in the assessed studies.
| Study | Drugs | |
|---|---|---|
| DOACs | nDOACs | |
| Raskob et al. (2018) | Edoxaban | Dalteparin |
| Raskob et al. (2016) | Edoxaban | Warfarin |
| Agnelli et al. (2015) | Apixaban | Enoxaparin/warfarin |
| Schulman et al. (2015) | Dabigatran | Warfarin |
| Prins et al. (2014) | Rivaroxaban | Enoxaparin/warfarin |
| Young et al. (2017) | Rivaroxaban | LMWH |
| McBane et al. (2016) | Rivaroxaban | LMWH |
| Angelini et al. (2018) | Rivaroxaban | Enoxaparin |
| Ageno et al. (2016) | Rivaroxaban | Dalteparin |
*RCT, randomized controlled trial; CS, cohort study; LMWH, low molecular weight heparin.